The number of recorded episodes of angina during the placebo period of 15_0 ± 2.1 (mean ± s.e.m.) per patient per week was significantly reduced to 11-2+±25 during the nifedipine period (P<0-05) . Similarly, the recorded number of glyceryl trinitrate tablets consumed during the placebo period of 12.6 ± 2.1 was significantly reduced to 9-1 + 2.0 tablets per patient per week during the nifedipine period (P<0405).
There was a statistically significant increase in both the duration of exercise to onset of chest pain (from 241 ± 16.3 seconds on placebo to 306 ± 38.4 seconds on nifedipine (P<0O05)) and the total work performed to the onset of chest pain during the nifedipine period compared to the control and placebo periods (P<0.05).
There was a significant increase (P<0-05) glyceryl trinitrate consumption in patients with angina pectoris, and also to increase the amount of pain-free work and total amount of work performed on exercise testing (Coltart, 1972; Elliot and Comparing the initial two control exercise tests performed whilst patients were taking beta-blockers and glyceryl trinitrate only, there was no significant difference in the duration of exercise before the onset of chest pain, in the total duration of the exercise test or in the total work performed at either the onset of chest pain or to the termination of exercise.
The duration of exercise in seconds to the onset of chest pain and the total amount of work performed to the onset of chest pain were significantly increased during the nifedipine period compared to the placebo and control periods, (P<0.05, 51.2 ± 3 sec and the placebo period of 58.7 ± 3.5 sec (P<0'05, Fig. 1 ).
Both systolic and diastolic resting blood pressures were reduced during the nifedipine period compared to the placebo period but the difference did not reach conventional levels of statistical significance. There was no significant difference in resting heart rate in the treatment periods.
One patient experienced a severe episode of angina within several hours of taking nifedipine during the seventh day of treatment which required admission. This patient also sustained the most marked fall in resting blood pressures within the group. Another patient experienced a gradual fall in exercise tolerance over the six consecutive exercise tests during the study and was admitted shortly after for coronary bypass grafting.
Discussion
Nifedipine is one of the most potent calcium channel blocking agents known and inhibits the slow inward current of calcium into the myocardial cell (Antman et al., 1980) . Although it has been shown to increase myocardial oxygen supply by a coronary vasodilator effect (Fleckenstein, 1977) and has been particularly effective in coronary artery spasm (Muller and Gunther, 1978) its main action in classical angina pectoris may well be by an extra cardiac effect (Moskowitz et al., 1979 ).
The double product (blood pressure x heart rate) at both the onset of chest pain and the end of the exercise was similar during the nifedipine and placebo periods. This indicates that any improvement in exercise capacity was due to a reduced oxygen demand rather than an augmented myocardial oxygen supply, which was probably the result of a reduction in cardiac after-load secondary to a decrease in systemic vascular resistance induced by nifedipine (Lynch et al., 1980) . Clinically nifedipine produced a statistically significant reduction in the number of episodes of angina and of glyceryl trinitrate consumption and was appreciated by most of the patients as being of real clinical benefit. However, on exercise testing the drug produced a greater increase in pain free exercise and total work attainable before chest pain than in total exercise time and total exercise capacity. Thus, an improvement in the amount of pain-free work on exercise may be the more important determinant of clinical response. As the placebo and nifedipine period were randomized, five patients entering the active period initially and four the placebo period initially, it seems unlikely that any difference, between these two periods was due to a training effect.
Most patients increased their exercise time before the onset of chest pain from an average of 4 to 5 min (28%). If expressed as total work performed at the onset of chest pain the average increase appears greater (87%) because the extra time before the onset of chest pain during a graduated exercise test is associated with a higher load of work as the exercise test proceeds.
Whereas there was no difference in time or work to the onset of chest pain between the control and placebo periods, total maximum work capacity did show an increase between control and placebo periods which nifedipine increased further by only a small amount. This significant increase in total exercise time and maximal work performed between the control and placebo period is difficult to explain. It may represent a training effect most pronounced between the initial control period and the other two periods that always followed. Alternatively, although both the onset of chest pain and the point of exhaustion are subjective end points, the latter point may be the less definable, more subjective and more susceptible to a placebo effect.
The study does show that quite small increases in measured work capacity may be associated with clinically significant benefits.
Interestingly, a severe exacerbation of angina during the nifedipine period occurred in one patient who also sustained the greatest hypotensive effect on the drug. Prolonged episodes of severe chest pain during nifedipine therapy have been well documented and although usually a first dose phenomenon can occur during the first week of treatment (Jariwalla and Anderson, 1978; Keider et al., 1980; Rodger and Stewart, 1978 (Opie and White, 1980; Anastassiades, 1980 
